BioSpace News Archive

Enzyvant announced the resubmission of the Biologics Licensing Application to the U.S. Food and Drug Administration for RVT-802, cultured human thymus tissue.

Centene Corporation announced its financial results for the first quarter ended March 31, 2021, reporting diluted earnings per share of $1.19 and adjusted diluted EPS of $1.63.

DaVita Inc. announced its 2025 Environmental, Social and Governance goals and released its new ESG reports, bolstering its commitment to corporate citizenship and helping create healthy communities.

Hygiene and health company Essity has signed an agreement today to acquire the remaining 25% of the shares in the Swedish medical solutions company ABIGO Medical AB. Essity acquired 75% of ABIGO Medical in February 2020 .

Liam Kelly, Chairman, President and CEO, Teleflex Incorporated, is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m..

Merck, known as MSD outside the United States and Canada, announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers.

Merck, known as MSD outside the United States and Canada, announced that members of Organon management will host a virtual investor event where they will present the Organon business strategy, opportunities for growth and financial outlook, followed by a question and answer session on Monday, May 3 at 10:00 am EDT.

Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 4, 2021 at 4:20 p.m. EDT.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of efficacy and safety results from a previously reported Phase 2b clinical trial with nebulized ensifentrine added on to maintenance bronchodilator therapy in symptomatic chronic obstructive pulmonary disease patients.